Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
delayed orgasm.
Popular Articles

Senate Judiciary Committee Vote On Sotomayor Reset For July 28
The Senate Judiciary Committee on Tuesday postponed its vote on Supreme Court nominee Sonia Sotomayor until July 28 at the request of Republican members who said they need one more week to review written answers she recently submitted to the panel, CongressDaily reports. Both Republicans and Democrats expect Sotomayor to be approved by the committee and confirmed by the Senate, CongressDaily reports (CongressDaily, 7/21).The delay came as Senate Republicans continued to weigh whether they would vote to confirm Sotomayor, the Wall Street Journal reports. Sen. Susan Collins (R-Maine) announced plans to vote for Sotomayor and issued a statement calling the judge "committed to applying the law impartially without bias or favoritism." Four other moderate Republicans have said they will support Sotomayor, and Senate Judiciary Committee Chair Patrick Leahy (D-Vt.) indicated that more might follow suit. "There are a number of Republicans who have announced they plan to vote for her," Leahy said, adding, "There are a number of others who"ve not made that announcement yet, but plan to vote for her" (Peterson, Wall Street Journal, 7/21). Leahy said he is confident that Sotomayor will be confirmed in time for the Supreme Court"s first meeting on Sept. 9.Some strong conservatives, including Senate Minority Leader Mitch McConnell (Ky.), have said they will oppose Sotomayor (Hirschfeld Davis, AP/Denver Post, 7/22). Among the Senate Republicans who have not announced their intentions are Sens. John Cornyn (Texas), who serves on the Judiciary Committee, and Judd Gregg (N.H.) (Wall Street Journal, 7/21).NARAL Endorses Sotomayor NARAL ProChoice America recently said that it will endorse Sotomayor, the AP/Seattle Times reports. The group said that Sotomayor"s testimony shows that she is a stronger supporter of privacy rights than the last two Supreme Court nominees -- Chief Justice John Roberts and Justice Samuel Alito. Sotomayor said several times during her confirmation hearings that privacy rights include a woman"s right to have an abortion, NARAL said. According to the AP/Times, NARAL did not endorse Sotomayor until now because of uncertainty over her views on abortion rights (Hirschfeld Davis, AP/Seattle Times, 7/21).
generic viagra
PTC Therapeutics Initiates Phase 2 Clinical Trial Of PTC299 In Patients With Neurofibromatosis Type 2
PTC Therapeutics, Inc. (PTC) announced the initiation of a Phase 2 clinical trial of PTC299 in adult patients with neurofibromatosis type 2 (NF2), a rare genetic disorder that causes the development of non-malignant brain tumors. PTC299 is a novel, orally administered investigational new drug that is designed to selectively block tumor-related vascular endothelial growth factor (VEGF). With its novel mechanism of action, PTC299 has the potential to meet significant unmet medical need in NF2 and other conditions resulting from the overexpression of VEGF.
News of the day
FDA Approves Hologic's Less Invasive Permanent Contraception System
FDA has given final approval to Hologic"s Adiana permanent contraception system, the Boston Herald reports. The company hopes to market the procedure as an alternative to tubal ligation surgery for the roughly 700,000 U.S. women who undergo the procedure each year. Adiana is similar to Conceptus" Essure, which has been on the market since 2002.Adiana involves a two-step procedure that can be performed in about 15 minutes in a doctor"s office. The process consists of inserting a catheter into the fallopian tubes and delivering a low level of radio frequency energy to make a small lesion on the inside lining of each tube. The catheter then implants silicone polymer inserts, about the size of a grain of rice, on top of the lesions. The tubes become blocked as healthy cell tissue attaches to the inserts (McConville, Boston Herald, 7/9).
Mental Health

Eupean Action Against Rare Cancers

European Action Against Rare Cancers is a new campaign that has been launched today to coincide with the publication of the European Commission"s Communication on Cancer. The new campaign urges European policy-makers to prioritise better treatment and care for patients with rare cancers within the framework of the new Commission Communication on cancer and other recent policy initiatives such as the Council Recommendation on Rare Diseases. Nearly half a million Europeans live with a rare cancer. Despite the rarity of each individual cancer type, rare cancers represent in total about 20% of all cancer cases, including all cancers in children. Rare cancers are classified in the group of rare diseases which is defined in the European Union as diseases with a prevalence of fewer than 5 cases out of a population of 10,000. As such, patients with rare cancers are faced with the same problems as other patients with a rare disease, such as lack of information, inefficient detection and practical obstacles to treatment and care, just because their condition is rare. With this background, we have established a Call to Action - an international petition to be endorsed by organisations and private individuals. The Call to Action appeals to policy-makers and all other relevant stakeholders to initiate targeted actions and policies that will address the challenges that rare cancers entail for the patients who are living with the disease, for the physicians who are treating the patients, and for the researchers who are working to acquire more knowledge in this field. Sandy Craine, Director of the Chronic Myeloid Leukaemia Support Group states: "Facing a rare cancer as a patient has great challenges: to get the proper diagnosis, to find a doctor with medical expertise in that specific rare cancer, and to access an effective therapy, if it exists." Paolo Casali, medical oncology expert on rare cancers and representative of the European Society for Medical Oncology (ESMO) states: "Policy makers are realizing the enormous public health threat of cancer and the need to address issues that relate to all patients, not only those with the most common cancer types. However, effective solutions require a broad European-based forum to discuss them. ESMO understood this need and organised a conference with the major European stakeholders in both rare diseases and rare cancers. The outcome of this conference is a united collaborative effort called "European Action Against Rare Cancers". This campaign is extremely valuable to the entire oncology community because it clearly identifies the challenges of rare cancers and outlines concrete, integrated and sustainable solutions which the various stakeholders can implement to help solve them." Guido Guidi, Head of Novartis Oncology Region Europe, adds to this: ""The fight against cancer relies on commitment from all relevant stakeholders working in partnership with open dialogue. Equally, the political and regulatory framework should work to ensure all cancer patients in Europe have access to the highest attainable standard of cancer care. We all recognize that to reconcile sustainable financing with improved patient access to optimal care, the whole EU system needs to work more effectively and efficiently. Improved cooperation among all stakeholder groups, as well as recognition of how each can contribute, is a precondition. The "European Action Against Rare Cancers" initiative is an excellent example of a partnership involving many stakeholders working to reach a common goal"". European Action Against Rare Cancers


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009